| Thursday, October 15th | |||
|---|---|---|---|
| Hall A | Hall B | ||
| 08:45-09:00 | Welcome Coffee | ||
| 09:00-12:00 | IACH 1: Workshop | ||
| 12:00-12:30 | Lunch Break | ||
| 12:30-13:00 | IACH 2: Awards Session | ||
| 13:00-14:15 | Transplant 1 | 13:00-14:15 | COMydAL 1: MDS I |
| Moderators: TBA | |||
| 13:00-13:15 | A new MDS classification ahead? TBA |
||
| 13:15-13:30 | AI in diagnosis and prognostication of MDS and CMML: TBA |
||
| 13:30-13:45 | Is there a border between AA and hMDS? TBA |
||
| 13:45-14:00 | Germline predisposition in MDS, diagnosis and impact on therapy: TBA |
||
| 14:00-14:15 | Panel discussion: All session faculty | ||
| 14:15-15:30 | Transplant 2 | 14:15-15:30 | COMydAL 2: MDS II |
| Moderators: Valeria Santini (Italy); TBA | |||
| 14:15-14:30 | Transplant for MDS in 2026? TBA |
||
| 14:30-14:45 | Diagnosis and treatment of VEXAS and MDS: TBA |
||
| 14:45-15:00 | Therapy of HR MDS: are target drugs the onlyl hope? TBA |
||
| 15:00-15:15 | Navigating the treatment of LR-MDS: TBA |
||
| 15:15-15:30 | Panel discussion: All session faculty | ||
| 15:30-16:45 | Industry Symposium | 15:30-16:45 | Industry Symposium |
| 16:45-17:00 | Coffee Break | ||
| 17:00-18:15 | Transplant 3 | 17:00-18:15 | COMydAL 3: CMML, MDS/MPN and others |
| Moderators: Valeria Santini (Italy); TBA | |||
| 17:00-17:15 | New directions in management of TP53 mutated myeloid neoplasms: Maximilian Stahl (USA) |
||
| 17:15-17:30 | Evolving use of oral HMAs in myeloid malignancies: Daniel Wiseman (UK) |
||
| 17:30-17:45 | Recommendation transplantation in CMML and MDS/MPN: TBA |
||
| 17:45-18:00 | Biology and treatment of CMML: TBA |
||
| 18:00-18:15 | Panel discussion: All session faculty | ||
IACH track
COMydAL track
COLYM track
MPNCo&D track
Transplant track
| Friday, October 16th | |||
|---|---|---|---|
| Hall A | Hall B | ||
| 08:30-09:45 | Transplant 4 | 08:30-09:45 | COMydAL 4: AML I |
| Moderators: Tamara Vasilj (Croatia); Amer Zeidan (USA) | |||
| MyeloMatch and pivotal AML studies to watch for in the next 3 years: TBA | |||
| An update on FLT3 inhibitors use in AML: TBA | |||
| An update on IDH inhibitors use in AML: Stéphane De Botton (France) | |||
| An update on menin inhibitors use in AML: Amer Zeidan (USA) | |||
| Panel discussion: All session faculty | |||
| 09:45-10:00 | Coffee Break | ||
| 10:00-11:15 | Transplant 5 | 10:00-11:15 | COMydAL 5: AML II |
| Moderators: Sanam Loghavi (USA): Amer Zeidan (USA) | |||
| How should TP53 mutated myeloid neoplasms be classified? TBA | |||
| Updates on clinical use of MRD for clinical management of AML: Christoph Röllig (Germany) | |||
| Learnings from HARMONY about genetics determinants of outcomes in AML: TBA | |||
| Harmonization efforts of classifications for AML and MDS: Sanam Loghavi (USA) | |||
| Panel disucssion: All session faculty | |||
| 11:15-12:30 | Industry Symposium | 11:15-12:30 | Industry Symposium |
| 12:30-13:00 | Lunch Break | ||
| 13:00-14:15 | COLYM 1: From Biology to Bedside: What Will Really Change Practice? |
13:00-13:05 | Opening: Claire Harrison (UK); Ruben Mesa (USA); Naveen Pemmaraju (USA) |
| 13:05-14:15 | MPNCo&D 1: Redefining disease and risk: are we stratifying patients correctly? | ||
| Moderators: TBA | Moderators: Florian Heidel (Germany); TBA | ||
| 13:00-13:05 |
Case report: TBA |
13:05-13:20 | Patient perspective on MPN priorities for 2026 and beyond: Werner Zinkland (Germany) |
| 13:05-13:15 | Discussion | 13:20-13:35 | Molecular risk models vs clinical judgement: are mutations driving overtreatment? Should we use them more in ET and PV: Jean-Jacques Kiladjian (France) |
| 13:15-13:30 | Molecular subtyping and functional genomics: what is ready for routine care? TBA | 13:35-13:50 | Clonal hematopoiesis vs early MPN: when does ‘watch and wait’ become unsafe? TBA |
| 13:30-13:45 | ctDNA as a decision-making tool: hype, hope, or hard evidence? Sven Borchmann (Germany) | 13:50-14:05 | Symptoms, spleen, survival: which outcome should drive first-line therapy choices in MF? Claire Harrison (UK) |
| 13:45-14:00 | Emerging biomarkers for response prediction to novel agents: Brian Hill (USA) | 14:05-14:15 | Panel discussion: All session faculty |
| 14:00-14:15 | Panel discussion: All session faculty | ||
| 14:15-15:30 | Industry Symposium | 14:15-15:30 | Industry Symposium |
| 15:30-16:45 | COLYM 2: Redefining Frontline Therapy: Risk, Response, and Reality | 15:30-16:45 | MPNCo&D 2: Anemia in myelofibrosis: mechanism-driven therapy or trial-and-error? |
| Moderators: TBA | Moderators: David Ross (Australia); TBA | ||
| 15:30-15:35 |
Case report: TBA |
15:30-15:45 | What causes anemia in MF — cytokines, hepcidin, marrow failure, or treatment effect? David Ross (Australia) |
| 15:35-15:45 | Discussion | 15:45-16:00 | ESAs, danazol, steroids: obsolete, underused, or still foundational? Susanne Isfort (Germany) |
| 15:45-16:00 | Biology-driven frontline strategies in aggressive B-cell lymphomas: Andrew Davies (UK) | 16:00-16:15 | Novel agents targeting anemia pathways in MF: Searching for the Holy Grail: Ruben Mesa (USA) |
| 16:00-16:15 | Frontline therapy in high-risk subgroups: elderly fit patients with LBCL: Farrukh Awan (USA) | 16:15-16:35 | Anemia as a prognostic marker vs a treatment-limiting toxicity: should it dictate therapy choice? Yes: Juan Carlos Hernandes-Boluda (Spain) No: TBA |
| 16:15-16:30 | Managing primary refractory and early relapsed aggressive B-cell lymphomas: optimizing salvage and bridging strategies: TBA | 16:35-16:45 | Panel discussion: All session faculty |
| 16:30-16:45 | Panel discussion: All session faculty | ||
| 16:45-17:00 | Coffee Break | ||
| 17:00-18:15 | IACH 3 | ||
| Saturday, October 17th | |||
|---|---|---|---|
| Hall A | Hall B | ||
| 08:30-09:45 | COLYM 3: Sequencing in Relapsed Lymphoma: Making Sense of Too Many Options | 08:30-09:45 | MPNCo&D 3: Next-generation targeted therapies: beyond JAK inhibition in MF |
| Moderators: TBA | Moderators: Susanne Isfort (Germany); Andreas Reiter (Germany) | ||
| 08:30-08:35 | Case report: TBA | 08:30-08:45 | Selective pathway targeting (e.g. hepcidin, ACVR1, BCL-2 family, Xpo1, MDM2): real differentiation or incremental gains? Jennifer O’Sullivan (UK) |
| 08:35-08:45 | Discussion | ||
| 08:45-09:00 | Bispecific antibodies vs cellular therapies in FL: how to choose in real-life practice: TBA |
08:45-09:00 | Early signals from novel agents targeting CALR in MF: how should clinicians interpret phase 1-2 data? Bethan Psaila (UK) |
| 09:00-09:15 | Treatment sequencing in relapsed / refractory MZL: what do we do next? TBA |
09:00-09:15 | Early data on novel JAK inhibitors: molecular markers, phenotype, or treatment history? John Mascarenhas (USA) |
| 09:15-09:30 | Treatment sequencing in relapsed / refractory MCL: what do we do next? Carlo Visco (Italy) |
09:15-09:35 | Combination strategies for upfront management: all patients INT-1 or above with splenomegaly and symptoms should receive combination therapy if trials are positive Yes: Francesco Passamonti (Italy) No: Florian Heidel (Germany) |
| 09:30-09:45 | Panel discussion: All session faculty | 09:35-09:45 | Panel discussion: All session faculty |
| 09:45-10:00 | Coffee Break | ||
| 10:00-11:15 | COLYM 4: Hodgkin Lymphoma: Optimizing Therapy Across Risk Groups | 10:00-11:15 | MPNCo&D 4: Transplant, disease evolution, and overlap biology |
| Moderators: TBA | Moderators: Anna Godfrey (UK); Juan Carlos Hernandes-Boluda (Spain) | ||
| 10:00-10:05 | Case report: TBA | 10:00-10:15 | Who should be referred for transplant today — and who is being missed? TBA |
| 10:05-10:15 | Discussion | ||
| 10:15-10:30 | Frontline therapy in advanced-stage classical Hodgkin lymphoma: balancing efficacy and toxicity: TBA |
10:15-10:30 | Timing allo-HSCT for atypical MPN: earlier, later, or never? Nicola Polverelli (Italy) |
| 10:30-10:45 | PET-adapted and response-adapted strategies: how low can we go? TBA |
10:30-10:45 | Overlap syndromes (SM-AHN, MPN with eosinophilia): single disease biology or parallel processes? Andreas Reiter (Germany) |
| 10:45-11:00 | Managing relapsed/refractory Hodgkin lymphoma: Checkpoint inhibitors, and beyond: Graham Collins (UK) |
10:45-11:00 | Lessons learned from two decades of experience with KIT inhibitors in systemic mastocytosis: Jason Gotlib (USA) |
| 11:00-11:15 | Panel discussion: All session faculty | 11:00-11:15 | Advanced systemic mastocytosis treatment in 2026: lessons for risk-adapted therapy in MPNs: Deepti Radia (UK) |
| 11:15-12:30 | Industry Symposium | 11:15-12:30 | Industry Symposium |
| 12:30-13:00 | Lunch Break | ||
| 13:00-14:15 | COLYM 5: Rare, Neglected, and Difficult Lymphomas | 13:00-14:15 | MPNCo&D 5: New options for Essential Thrombocythemia and Polycythemia Vera — are they needed and when should we use them? |
| Moderators: TBA | Moderators: Claire Woodley (UK); TBA | ||
| 13:00-13:05 | Case report: TBA | 13:00-13:15 | Interferon — which patients with ET and PV should have it and what is the treatment target? Lina Benajiba (France) |
| 13:05-13:15 | Discussion | ||
| 13:15-13:30 | Peripheral T-cell lymphomas: are we finally improving outcomes? Eva Domingo-Domènech (Spain) |
13:15-13:30 | Hepcidin mimetics — how will they be used for PV patients? Naveen Pemmaraju (USA) |
| 13:30-13:45 | Primary CNS and extranodal lymphomas: unmet needs and new strategies: TBA |
13:30-13:45 | Emerging precision therapies in ET: Anna Godfrey (UK) |
| 13:45-14:00 | Management of post-transplant lymphoproliferative disorders (PTLD) and immunodeficiency-associated lymphomas: TBA |
13:45-14:00 | MPN Symptom Burden / Navigating ET and PV from Patient and Caregiver Perspective: Clinical Pearls from the Frontlines: Claire Woodley (UK) |
| 14:00-14:15 | Panel discussion: All session faculty | 14:00-14:15 | Panel discussion: All session faculty |
| 14:15-15:30 | IACH 4 | ||
| 15:30-15:45 | Coffee Break | ||
| 15:45-16:15 | IACH 5 | ||